The Pharma Fast 50
PharmaTimes presents Alantra’s annual look at the fastest-growing pharma companies
Last year the inaugural Pharma Fast 50 list showed us who the fastest-growing companies in the industry were, and we’re excited to be teaming up with Alantra again for a look at how things have changed for 2018 (p28).
Not only does the list tell the the industry which companies it needs to be keeping its eye on, but the accompanying analysis provides an in-depth look at the most important trends affecting the industry right now.
Elsewhere in the issue we look at how blockchain could change the pharma supply chain (p37), the latest trends in M&A (p36), the ups and downs of modern pharma R&D (p20) and an interesting collaborative project that aims to change health technology assessment in Duchenne muscular dystrophy (p22).
And don’t forget that March will be a big month for the PharmaTimes competitions – although both our Clinical Researcher competitions have now closed (with a record number of entries!) we’ll be launching the 2018 Communications Team of the Year awards and the Sales awards, as well as Marketer of the Year, which will be celebrating its 25th anniversary. We also have a brand new competition launching this year – Medical Excellence Awards for MSL, Scientific Affairs and Medical Affairs. Look out for more info in upcoming issues.
I hope you enjoy the issue.
PharmaTimes presents Alantra’s annual look at the fastest-growing pharma companies
Counterfeit drugs are a billion-dollar industry. Could blockchain – the technology behind bitcoin – be the answer?
Mark Brunning’s hepatitis C is now under control, but at its worst the disease felt like “death from a thousand cuts”
The biggest deal trends today and in the near future
For modern pharma business innovation, the choice is march or die
Local population needs underpin the new NHS care models - so how can pharma help develop a tailored approach?
The promising signs and the worrying trends of modern R&D
A new alliance in Duchenne muscular dystrophy aims to change the landscape of orphan drug assessment
The business unit director, oncology, Merck UK & Ireland talks about the future of his company and the UK industry
Portuguese pharma firm BIAL provides an interesting case study on improving access to scientific information